Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Vitamin D (D04.808.812.768); Women (M01.975); Osteoporosis (C05.116.198.579); Pharmacologic Actions (D27.505); Therapeutic Uses (D27.505.954); Alendronate (D02.705.429.500.100); Peptide Hormones (D06.472.699); Peptide Hormones (D12.644.548); Teriparatide (D06.472.699.590.850); Teriparatide (D12.644.548.587.850); Calcitonin (D06.472.699.150); Calcitonin (D12.644.400.095); Calcitonin (D12.644.548.150); Calcitonin (D12.776.641.650.095); Estrogen Replacement Therapy (E02.319.452.150); Selective Estrogen Receptor Modulators (D27.505.696.399.450.360.827); Selective Estrogen Receptor Modulators (D06.347.360.827); Raloxifene (D02.455.426.559.389.150.700.900.775); Osteoporosis; Postmenopausal (C05.116.198.579.610); Calcium (D01.268.552.100); Calcium (D01.552.539.288)